Lapatinib hæmmer CYP3A (Ki 0, 6- 2, 3 µg/ ml) og CYP2C8 (0, 3 µg/ ml) in vitro ved klinisk relevante koncentrationer.
Lapatinib inhibits CYP3A (Ki 0.6 to 2.3 µg/ ml) and CYP2C8 (0.3 µg/ ml) in vitro at clinically relevant concentrations.